Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFH312 in UDCA-inadequate responder primary biliary cholangitis (phase II)
CTR20261503Phase 2Active
- Sponsor
- GenFleet Therapeutics
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GFH312 in primary biliary cholangitis (PBC), sponsored by GenFleet Therapeutics. Started Apr 2026; status: active.
02
Drugs
GFH312
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on CTR20261503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261503.